Upgrade to BuyandBill.com Pro to access this report and the complete suite of analytics tools.
| Manufacturer ▼ | Drug Name | Indication | Stage | Status | Route of Administration | Drug Class |
|---|---|---|---|---|---|---|
| Sanofi | Venglustat | Fabry disease | Phase 3 | Ongoing | Oral | Genetic Disorder |
| Sanofi | Losmapimod - (REACH) | Facioscapulohumeral muscular dystrophy (FSHD) | Phase 3 | Trial Discontinued | Oral | Genetic Disorder |
| Sanofi | SAR442168 (PRN2246) | Multiple sclerosis | Phase 3 | Trial Completed | oral | Neurology |
| Sanofi | Rilzabrutinib PRN1008 - (PEGASUS) | Pemphigus | Phase 3 | Trial Discontinued | Oral | Immunology |
| Sanofi | Efpeglenatide | Type 2 diabetes | Phase 3 | Subcutaneous | Endocrinology | |
| Sanofi | Itepekimab - (AERIFY) | Chronic obstructive pulmonary disease (COPD) | Phase 3 | Data Released | Subcutaneous | Respiratory |
| Sanofi | duvakitug | Inflammatory bowel disease (IBD) | Phase 3 | Trial Planned | oral | Gastroenterology |
| Sanofi | Tusamitamab ravtansine (anti-CEACAM5 ADC) | Non-small cell lung cancer (NSCLC) | Phase 3 | Data Released | Intravenous | Oncology |
